There are as many ways to create in vivo proposals on the Scientist.com marketplace as there are researchers to request them, so how do we ensure that all requests are being compared equally? Scientist.com has streamlined the process by enabling side-by-side comparisons of proposals across multiple vendors based on key indicators such as quality, price, supplier rating and turnaround time.

Upsetting the status quo is never easy, especially when it comes to scientific research. Just ask AstraZeneca duo Natasha A. Karp, Associate Principal Scientist/ Biostatistician and Neil Reavey, Associate Director, Research Assurance, who explore ways of overcoming the issue of sex bias in a paper entitled, “Sex Bias in Preclinical Research and Exploration of How to Change the Status Quo.”

Most cellular processes are part of specific molecular pathways. A deep knowledge of each step of these pathways is important to tackle some of the key open questions within the life sciences and fight diseases.

Therapeutic antibody drugs have recently experienced explosive growth due in large part to the fact that immunotherapies stimulate the immune system to attack cancer cells. Within oncology research alone, more than 20 therapeutic antibody drugs received FDA approval for new treatments or indications during 2015 to 2018. Additionally, more than 300 therapeutic antibody drugs are in ongoing clinical trials.

Breathtaking progress in life sciences has brought us innovations such as high-throughput and individually affordable genomic sequencing as well as next-generation flow cytometry that can phenotype dissociated cells for their expression of dozens of markers simultaneously.